MONDAY, Dec. 16, 2019 -- For the first time in more than a decade, a leading pediatricians' group has issued new autism guidelines that emphasize early intervention.
Updated recommendations from the American Academy of Pediatrics (AAP) say screenings should be conducted at 9-, 18- and 30-month well-child visits and specific screening for autism should be done at 18 and 24 months.
TUESDAY, Oct. 22, 2019 -- A new drug to treat most cystic fibrosis patients has been approved by the U.S. Food and Drug Administration.
Trikafta (elexacaftor/ivacaftor/tezacaftor) is the first triple combination therapy available to treat patients with the most common cystic fibrosis mutation. Its list price is $311,000 a year, same as one of the maker's earlier treatments for the genetic disease.